Dr Reddy's Laboratories Change in Accounts Receivable 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly change in accounts receivable history and growth rate from 2010 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Dr Reddy's Laboratories change in accounts receivable for the quarter ending December 31, 2024 was $-0.141B, a 90.54% increase year-over-year.
- Dr Reddy's Laboratories change in accounts receivable for the twelve months ending December 31, 2024 was $-0.297B, a 75.74% increase year-over-year.
- Dr Reddy's Laboratories annual change in accounts receivable for 2024 was $-0.097B, a 38.57% increase from 2023.
- Dr Reddy's Laboratories annual change in accounts receivable for 2023 was $-0.07B, a 68.75% decline from 2022.
- Dr Reddy's Laboratories annual change in accounts receivable for 2022 was $-0.224B, a 900% decline from 2021.
Dr Reddy's Laboratories Annual Change in Accounts Receivable
(Millions of US $) |
| 2024 |
$-97 |
| 2023 |
$-70 |
| 2022 |
$-224 |
| 2021 |
$28 |
| 2020 |
$-165 |
| 2019 |
$26 |
| 2018 |
$-32 |
| 2017 |
$47 |
| 2016 |
$13 |
| 2015 |
$-175 |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.261B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
